Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12655883 | 0.90 | HCRTR1 (0.50) | HCRTR1HCRTR2L3MBTL1ALDH1A1GPR119 | |
| SCHEMBL12627185 | 0.90 | HCRTR1 (0.50) | HCRTR1HCRTR2L3MBTL1ALDH1A1MMP13 | |
| SCHEMBL12656193 | 0.89 | L3MBTL1 (0.57) | HCRTR1HCRTR2L3MBTL1ALDH1A1GPR119 | |
| SCHEMBL12627108 | 0.89 | HCRTR1 (0.48) | HCRTR1HCRTR2L3MBTL1ALDH1A1GPR119 | |
| SCHEMBL15426424 | 0.89 | HCRTR1 (0.48) | HCRTR1HCRTR2L3MBTL1ALDH1A1 | |
| SCHEMBL12623931 | 0.89 | HCRTR1 (0.48) | HCRTR1HCRTR2L3MBTL1ALDH1A1GPR119 | |
| SCHEMBL12626970 | 0.80 | USP2 (0.48) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL23161080 | 0.80 | L3MBTL1 (0.51) | HCRTR1HCRTR2L3MBTL1ALDH1A1 | |
| SCHEMBL12627276 | 0.79 | L3MBTL1 (0.47) | HCRTR1HCRTR2L3MBTL1ALDH1A1MMP13 | |
| SCHEMBL12621845 | 0.79 | L3MBTL1 (0.65) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10222368-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| WO-2015054027-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363239-B2 | Method for inhibiting growth of cancer cells | FLNA, FLNB, FSCN1 | HCRTR1 3430/4885HCRTR2 3778/4885L3MBTL1 1041/4885 |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885L3MBTL1 1789/4885 |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885L3MBTL1 1789/4885 |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885L3MBTL1 1789/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885L3MBTL1 1789/4885 |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | FLNA, FLNB, FSCN1 | HCRTR1 3430/4885HCRTR2 3778/4885L3MBTL1 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.